To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

This bill would roll back the FDA’s January 2023 changes to how the abortion pill mifepristone is dispensed. It cancels those changes and blocks the Department of Health and Human Services from making similar changes in the future. The 2023 update had removed the in‑person pickup rule and allowed certified retail pharmacies to dispense mifepristone with a prescription from a certified prescriber; undoing it would likely mean a return to stricter, in‑person dispensing rules at clinics, medical offices, or hospitals.

Mifepristone is approved to end a pregnancy through 10 weeks when used with misoprostol. The FDA oversees it through a special safety program. Under the 2023 changes, mail‑order and retail pharmacies could dispense it if certified; this bill would end those options by nullifying that policy and prohibiting similar policies going forward .

Key points

• Who is affected: Patients seeking medication abortion, health care providers who prescribe it, and pharmacies that dispense it.
• What changes: Ends the 2023 allowance for certified retail and mail‑order pharmacy dispensing and blocks similar future changes, likely reverting to in‑person dispensing at specified health care settings .
• When: If enacted, the 2023 modifications would be nullified; similar future changes would be prohibited.